Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657150 · ClinicalTrials.gov registry record · Phase 3
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,055
- Enrollment target
NCT00657150 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,055 participants.
The verdict
NCT00657150, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,055 participants
- Enrollment target
Study Summary
The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily. Safety and efficacy will be compared between the treatment groups.
Interventions
- DRUG Enoxaparin
- DRUG Dabigatran etexilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,055 participants |
| Start Date | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657150
The ClinicalTrials.gov registry entry for NCT00657150 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,055 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enoxaparin is the first listed.
NCT00657150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00657150 about?
NCT00657150 is a clinical study titled "Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty". The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily. Safety and efficacy will be compared between the treatment groups.
What is the current status of trial NCT00657150?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,055 participants. The study started on 2008-03.
What interventions are being tested in trial NCT00657150?
The interventions under investigation include: Enoxaparin (DRUG), Dabigatran etexilate (DRUG).
Who is sponsoring clinical trial NCT00657150?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.